Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

RALEIGH, N.C., April 5, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today completion of enrollment in its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

(Logo: https://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"The completion of enrollment in our Phase 3 efficacy study marks another very important milestone in our clinical development program for BEMA Buprenorphine in the management of chronic pain," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "We are very pleased to have achieved our aggressive recruitment and enrollment goals.  This milestone keeps us on target for reporting top-line study results in the third quarter of this year and is consistent with a timeline that would allow for a New Drug Application (NDA) to be filed in the second quarter of 2012."

BDSI believes that there remains a significant unmet medical need for potent new analgesics for the treatment of chronic pain.  The company believes that buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products.  In addition, BEMA Buprenorphine has the potential to be the first oral transmucosal form of buprenorphine to treat chronic pain in the U.S.  According to Wolters Kluwer, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BEMA Buprenorphine has the potential to exceed $500 million in peak annual sales.

Additional Information on Phase 3 Study Design (BUP-301)

This Phase 3 trial of BEMA Buprenorphine (referred to as BUP-301) is
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... --  MultiVir Inc. ("MultiVir"), a clinical-stage gene therapy ... the treatment of multiple oncological indications, today announced that ... S-1 with the U.S. Securities and Exchange Commission ("SEC") ... of its common stock. The number of shares to ... offering have not yet been determined. MultiVir has applied ...
(Date:3/30/2015)... -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE ) announced ... to the position of Executive Vice President & Chief ... responsible for all legal, compliance and intellectual property functions. ... Sciences International, Inc., where he was Senior Vice President ... that led that company to over a six fold ...
(Date:3/30/2015)... Alere Inc. (NYSE: ALR ), a ... today in support of President Barack Obama,s ... "As the global leader in rapid diagnostics for ... for establishing a National Action Plan with measurable goals ... antibiotic resistance. We look forward to continuing to work ...
Breaking Medicine Technology:MultiVir Files Registration Statement for Proposed Initial Public Offering 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 2Sorrento Announces Appointment Of George Ng As EVP & Chief Legal Officer 3Alere Applauds President's National Action Plan to Combat Antibiotic-Resistant Bacteria 2
(Date:3/30/2015)... March 30, 2015 Wright & Schulte ... lawsuits, notes that the number of Syngenta corn ... underway in U.S. District Court, District of Kansas, have ... 2014. "According to an update released by the U.S. ... at least 493 Syngenta lawsuits are now consolidated in ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 A new ... in California Superior Court on behalf of a child ... defect after his mother was prescribed the anti-nausea medication ... March 6th filing in Alameda Superior Court, the baby’s ... vomiting that she experienced in the early months of ...
(Date:3/30/2015)... Los Angeles, CA (PRWEB) March 30, 2015 ... “6 New Ways to Blast Away Fat,” details six new ... these treatments require injections and one is a topical product. ... ( UltraShape and Liposonix ) or freezing cold ... “There are so many options now available to us to ...
(Date:3/30/2015)... 2015 In a recent report published ... Chris Christie is championing effective drug and alcohol treatment ... scrambling to recover funds to stabilize the addiction treatment ... victims of drug and alcohol addiction. Harbor Village Detox ... by substance use disorders in New Jersey, in hopes ...
(Date:3/30/2015)... 2015 This report studies the ... the forecast period of 2014 to 2019. This ... of 6.5% from 2014 to 2019. , Further ... report, the global pharmacovigilance and drug safety software ... the basis of functionality, namely, adverse event reporting ...
Breaking Medicine News(10 mins):Health News:Syngenta Corn Lawsuit Claims Continue To Be Filed By Non GMO Corn Farmers Reports Wright & Schulte LLC 2Health News:Syngenta Corn Lawsuit Claims Continue To Be Filed By Non GMO Corn Farmers Reports Wright & Schulte LLC 3Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 2Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 3Health News:New Zofran Lawsuit Alleging Birth Defects Filed This Month in California Superior Court 4Health News:UltraShape and CoolSculpting: Two New Fat-Busting Technologies 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 2Health News:Harbor Village Detox Extends Addiction Treatment to NJ & Suggests 7 Ways to Find the Best Recovery Center 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4
... Brain Institute (QBI) have now found a process that ... from dementia and acquired brain injury. ,The research ... associated with memory function and where the brain's ability ... with age. ,The study by Dr Natalie Bull ...
... conducted by researchers at University of Texas Southwestern Medical ... problem //faced by diabetics by increasing their blood pressure. ... professor and chief of the division of nutrition and ... a high-carb diet on blood pressure with a diet ...
... Germany’s drugs firm Grunenthal has developed a new drinking ... bitter medicine// to their children. The straw contains and ... neutral taste. The straw also contains a filter which ... been taken. ,The tasteless cover of the granulated ...
... Harming Themselves To Get Relief From Frustrations. ,UK based ... the country inflict injuries upon themselves due to feelings ... upon themselves has been contemplated by 20% of the ... have actually harmed themselves. ,The Priory survey ...
... implicated as a causative factor in many different forms of ... cancer and respiratory diseases // . For example, 1/3rd of ... are being taken by members of the scientific community to ... and to help curb the same. ,A new ...
... claim that the weight gained during the holiday season is ... ,The weight gain starts from the Thanksgiving weekend ... battle of the holiday bulge., ,To stop this bulge ... have more fruits and non-fat yogurt, drink skimmed milk, drink ...
Cached Medicine News:Health News:Research Targets treatment for dementia and brain injuries 2Health News:Carbohydrate-rich Diet In Diabetes Raises Blood Pressure 2Health News:Most Smokers Continue To Smoke Despite Developing Cancer 2
Protologics Corporation announces ProtoCLAIMS, Web-based electronic claims product that links and reconciles desktop claims with insurance payers who offer direct claims processing....
... and Collections Administrator has a maximum ... models and personalized paper or electronic ... ability to facilitate rebilling, ledger notes, ... from the Onscreen Collections Worksheet and ...
Visionary OFFICE™ PM offers a Windows interface featuring medical billing, appointment scheduling and patient information....
A.I.med's medical billing software is a medical billing software. The billing module integrates with A.I.med's Electronic Medical Record software. A.I.med's medical billing module also integrates wit...
Medicine Products: